Somewhat Critical News Coverage Somewhat Unlikely to Affect Biolase (BIOL) Stock Price

Media headlines about Biolase (NASDAQ:BIOL) have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biolase earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned headlines about the medical technology company an impact score of 47.5541789151207 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

• ETFs with exposure to BIOLASE, Inc. : August 25, 2017 (finance.yahoo.com)
• Dental Surgical Equipment Market Size to Surge Vigorously during the Forecast Period 2020 (medgadget.com)
• New study: Directed energy-based surgical systems market report (whatech.com)
• Dental Diagnostic and Surgical Equipment Market Forecast 2023 (sbwire.com)
• Europe Dental Equipment Market to grow at a CAGR of 4.9% during 2016 to 2021 | Market Data Forecast (medgadget.com)

Biolase (BIOL) traded down 3.51% on Friday, reaching $0.55. The company had a trading volume of 129,256 shares. Biolase has a 52-week low of $0.48 and a 52-week high of $1.98. The company’s 50-day moving average is $0.75 and its 200-day moving average is $1.12. The company’s market capitalization is $41.79 million.

Biolase (NASDAQ:BIOL) last issued its quarterly earnings results on Monday, August 7th. The medical technology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. Biolase had a negative net margin of 31.64% and a negative return on equity of 64.44%. The firm had revenue of $12.61 million for the quarter. Equities analysts anticipate that Biolase will post ($0.16) EPS for the current fiscal year.

Separately, ValuEngine downgraded Biolase from a “hold” rating to a “sell” rating in a research note on Monday, July 24th.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was originally published by [[site]] and is owned by of [[site]]. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at [[permalink]].

About Biolase

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.